Heartflow’s (HTFL) Buy Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Heartflow (NASDAQ:HTFL) in a research note published on Monday,Benzinga reports. Canaccord Genuity Group currently has a $40.00 price target on the stock.

Several other research firms have also weighed in on HTFL. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Stifel Nicolaus increased their price objective on Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 13th. JPMorgan Chase & Co. boosted their target price on shares of Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Finally, Wells Fargo & Company initiated coverage on shares of Heartflow in a research report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Heartflow presently has an average rating of “Moderate Buy” and a consensus target price of $38.50.

Heartflow Stock Performance

HTFL opened at $22.21 on Monday. The business’s 50-day simple moving average is $28.00 and its 200 day simple moving average is $30.83. Heartflow has a 52-week low of $20.13 and a 52-week high of $41.22. The firm has a market capitalization of $1.89 billion and a PE ratio of -12.27.

Insider Transactions at Heartflow

In related news, CEO John C.M. Farquhar sold 22,562 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total transaction of $619,552.52. Following the transaction, the chief executive officer directly owned 591,656 shares of the company’s stock, valued at approximately $16,246,873.76. The trade was a 3.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Campbell Rogers sold 65,153 shares of the stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $24.49, for a total value of $1,595,596.97. Following the completion of the sale, the insider owned 76,034 shares in the company, valued at approximately $1,862,072.66. This trade represents a 46.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 2,104,837 shares of company stock valued at $58,761,759.

Hedge Funds Weigh In On Heartflow

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd bought a new position in shares of Heartflow in the fourth quarter valued at about $27,000. TFC Financial Management Inc. acquired a new stake in shares of Heartflow during the 3rd quarter worth about $40,000. Russell Investments Group Ltd. bought a new stake in shares of Heartflow during the 4th quarter worth about $45,000. Legal & General Group Plc acquired a new position in Heartflow in the 3rd quarter valued at about $59,000. Finally, Strs Ohio bought a new position in Heartflow in the 4th quarter valued at about $99,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.